NSE · BAFNAPH
Bafna Pharmaceuticals Limited
Historical price visualisation is temporarily undergoing corporate data-licensing maintenance. Full interactive price and chart data will return following our upcoming authorized NSE/BSE data-feed deployment. Derived metrics (valuation ratios, market-cap rank), company financials, shareholding, corporate actions, and mutual-fund holdings remain available.
Market cap rank
#1,644
of 5,072 stocks
▲ 591W
Peak #1,644 · 27 Sep 2026
A smallcap name in Healthcare, Bafna Pharmaceuticals Limited carries a steep earnings multiple that prices in strong future growth, remains firmly promoter-controlled, with promoters holding 75%, and is growing revenue modestly.
Market Cap
828.09 Cr
P/E Ratio
74.64
P/B Ratio
8.61
ROE
11.54%
ROCE
12.36%
Dividend Yield
—
52W High
—
52W Low
—
Quarterly financials
| Metric | Q1 2026-27 | Q4 2025-26 | Q3 2025-26 | Q2 2025-26 |
|---|---|---|---|---|
| Revenue | 26.58 Cr | 42.24 Cr | 38.29 Cr | 35.47 Cr |
| Net Profit | 7.51 L | 2.75 Cr | 1.84 Cr | 3.12 Cr |
| EPS | 0.03 | 1.16 | 0.78 | 1.32 |
| Operating Profit | 1.01 Cr | 3.65 Cr | 2.70 Cr | 3.99 Cr |
Shareholding pattern
Promoter
75.00%
Public
25.00%
Mutual fund holdings
Mutual fund holdings data for this stock hasn't been ingested yet — check back soon.
Recent corporate actions
| Ex-Date | Type | Details |
|---|---|---|
| 17 Sep 2024 | Other | Annual General Meeting |
| 20 Jul 2022 | Other | Annual General Meeting |
| 05 Aug 2021 | Other | Annual General Meeting |
| 23 Jul 2020 | Other | Annual General Meeting |
Need this data in your app?
Full price history, technical indicators, and every field above via one REST API call.